Slowing Thoracic Aortic Aneurysm Growth with Statins: A Meta-Analysis.

IF 2.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Amie Marie Kolimas, Gargya Malla, Abhimanyu Chadha, Enkhtsogt Sainbayar, Joshua Sethi, Ziad Hindosh, Priyanka Hadvani, Hoang Nhat Pham, Juan Sordia
{"title":"Slowing Thoracic Aortic Aneurysm Growth with Statins: A Meta-Analysis.","authors":"Amie Marie Kolimas, Gargya Malla, Abhimanyu Chadha, Enkhtsogt Sainbayar, Joshua Sethi, Ziad Hindosh, Priyanka Hadvani, Hoang Nhat Pham, Juan Sordia","doi":"10.2174/011573403X343512250127075044","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thoracic aortic aneurysms (TAAs) are worrisome for their propensity to dissect. Previous studies have demonstrated the potential benefits of statin use, particularly with slowing aortic aneurysm growth. The aim of this meta-analysis was to consolidate existing research to ascertain if statins effectively reduce TAA growth.</p><p><strong>Methods: </strong>Multiple databases were searched to identify studies assessing TAA growth in patients on statins (cases) and those not on statins (controls). The primary outcome was TAA (ascending/ aortic arch) growth rate per year. Standard mean difference (SMD) and 95% confidence intervals (95% CI) were estimated with a random-effects model using the inverse-variance technique. We assigned I2>50% as an indicator of statistical heterogeneity. P-value <0.05 was considered significant. Data analysis was performed using SPSS v.25.0.</p><p><strong>Results: </strong>Four studies comprising 757 cases (male 64%, mean age 65±14 years) and 1,696 controls (male 62%, mean age 61±18 years) were included. The baseline diameters of TAA for cases and controls were 40.35±8.75mm and 42.39±12.60mm, respectively. Pooled results suggested statins to be associated with slower growth of TAAs with pooled SMD -0.70 mm/year [95% CI (-1.23 - -0.16); p=0.01]. Heterogeneity statistics among 4 studies was 95%.</p><p><strong>Conclusion: </strong>This pooled meta-analysis showed statins as associated with slower growth of TAAs. However, given the heterogeneity of the included studies in this meta-analysis, results should be interpreted with caution.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011573403X343512250127075044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Thoracic aortic aneurysms (TAAs) are worrisome for their propensity to dissect. Previous studies have demonstrated the potential benefits of statin use, particularly with slowing aortic aneurysm growth. The aim of this meta-analysis was to consolidate existing research to ascertain if statins effectively reduce TAA growth.

Methods: Multiple databases were searched to identify studies assessing TAA growth in patients on statins (cases) and those not on statins (controls). The primary outcome was TAA (ascending/ aortic arch) growth rate per year. Standard mean difference (SMD) and 95% confidence intervals (95% CI) were estimated with a random-effects model using the inverse-variance technique. We assigned I2>50% as an indicator of statistical heterogeneity. P-value <0.05 was considered significant. Data analysis was performed using SPSS v.25.0.

Results: Four studies comprising 757 cases (male 64%, mean age 65±14 years) and 1,696 controls (male 62%, mean age 61±18 years) were included. The baseline diameters of TAA for cases and controls were 40.35±8.75mm and 42.39±12.60mm, respectively. Pooled results suggested statins to be associated with slower growth of TAAs with pooled SMD -0.70 mm/year [95% CI (-1.23 - -0.16); p=0.01]. Heterogeneity statistics among 4 studies was 95%.

Conclusion: This pooled meta-analysis showed statins as associated with slower growth of TAAs. However, given the heterogeneity of the included studies in this meta-analysis, results should be interpreted with caution.

他汀类药物减缓胸主动脉瘤生长:荟萃分析。
背景:胸主动脉瘤(TAAs)因其解剖倾向而令人担忧。先前的研究已经证明了他汀类药物的潜在益处,特别是在减缓主动脉瘤生长方面。本荟萃分析的目的是巩固现有的研究,以确定他汀类药物是否有效地减少TAA的生长。方法:检索多个数据库,以确定评估他汀类药物患者(病例)和非他汀类药物患者(对照组)TAA生长的研究。主要终点是每年的TAA(升/主动脉弓)增长率。标准均差(SMD)和95%置信区间(95% CI)用随机效应模型使用反方差技术估计。我们将I2 bb0 50%作为统计异质性的指标。p值结果:纳入4项研究,757例(男性64%,平均年龄65±14岁)和1696例对照(男性62%,平均年龄61±18岁)。病例组和对照组TAA基线直径分别为40.35±8.75mm和42.39±12.60mm。综合结果显示,他汀类药物与taa生长缓慢相关,累积SMD为-0.70 mm/年[95% CI (-1.23 - -0.16);p = 0.01)。4项研究的异质性统计为95%。结论:这项综合荟萃分析显示,他汀类药物与taa生长缓慢相关。然而,考虑到本荟萃分析纳入研究的异质性,结果应谨慎解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Cardiology Reviews
Current Cardiology Reviews CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.70
自引率
10.50%
发文量
117
期刊介绍: Current Cardiology Reviews publishes frontier reviews of high quality on all the latest advances on the practical and clinical approach to the diagnosis and treatment of cardiovascular disease. All relevant areas are covered by the journal including arrhythmia, congestive heart failure, cardiomyopathy, congenital heart disease, drugs, methodology, pacing, and preventive cardiology. The journal is essential reading for all researchers and clinicians in cardiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信